Valuation dashboard for Denali Therapeutics Inc. (DNLI) with P/E N/A, P/B 4.23, EV/EBITDA -5.7 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline.
Analysis Summary
Trailing-twelve-month margins: gross margin -61.0%, operating margin -150.6%, net margin -141.9%.
At $18.86 (closing price, November 2, 2026), DNLI has negative trailing earnings (P/E not meaningful) and an ROE of -55.27%. Market capitalisation stands at $3.0B.
Balance sheet quality for DNLI: debt-to-equity ratio of 0.03, current ratio of 8.37 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.23 |
| EV / EBITDA | -5.7 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | $3.0B | 4.23 | -55.3% | |
| NBIX | Neurocrine Biosciences, Inc. | $14.8B | 21.57 | 3.81 | 19.7% |
| IONS | Ionis Pharmaceuticals, Inc. | $6.9B | 15.51 | -110.8% | |
| PRAX | Praxis Precision Medicines, Inc. | $7.6B | 5.95 | -34.1% | |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.5B | 13.04 | -52.9% | |
| BHVN | Biohaven Ltd. | $2.3B | -22.7% |
Price
| Price | $18.86 (closing price, November 2, 2026) |
| Market Cap | $3.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -55.27% |
| Return on Invested Capital | -50.82% |
| Return on Assets | -44.17% |
| Gross Margin | -61.04% |
| Operating Margin | -15,058.19% |
| Net Margin | -14,191.20% |
Related companies: NBIX · IONS · PRAX · AMLX · BHVN
Explore sector: Healthcare · Biotechnology
More sections of DNLI: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks